Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)6.10
  • Today's Change0.10 / 1.67%
  • Shares traded998.70k
  • 1 Year change+309.40%
  • Beta1.4259
Data delayed at least 15 minutes, as of Feb 16 2026 04:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Jacobio Pharmaceuticals Group Co Ltd is an investment holding company mainly engaged in the research and development of new drugs at the clinical stage. The Company is primarily responsible for the independent discovery and development of innovative tumor therapies. The Company's main drug development projects include JAB-21822 and JAB-3312 clinical stage allosteric SHP2 inhibitors. The Company mainly operates its businesses in China market.

  • Revenue in HKD (TTM)227.81m
  • Net income in HKD-51.64m
  • Incorporated2018
  • Employees211.00
  • Location
    Jacobio Pharmaceuticals Group Co LtdBuilding F2, No. 88Kechuang 6th Street, Beijing EconomicTechnological Development AreaBEIJING ChinaCHN
  • Phone+86 1 056315466
  • Fax+86 1 056315314
  • Websitehttps://www.jacobiopharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hanx Biopharmaceuticals (Wuhan) Co Ltd-100.00bn-100.00bn2.62bn-------------------------------------------------------52.30------
Clover Biopharmaceuticals Ltd58.57m-1.03bn2.86bn243.00------48.76-0.8194-0.81940.0466-1.490.04330.054747.89195,238.00-76.07-75.37---188.1462.57---1,756.85-13,419.000.2541-------2.13---552.11---24.90--
BioDlink International Co Ltd1.21bn8.21m3.25bn604.00370.883.9235.552.690.01130.01131.661.070.72752.355.491,975,381.000.495-11.370.6586-14.8971.1073.140.6805-24.911.681.830.3519--40.7089.20192.05--27.04--
Hua Medicine419.33m1.22bn3.30bn285.002.552.562.627.861.231.230.42481.220.24111.765.712,496,030.0069.99-21.8382.64-25.3152.55--290.30-395.247.00--0.2038--234.02---18.42---17.81--
Medtide Inc-100.00bn-100.00bn3.61bn520.00--2.17----------11.72------------------------4.48--0.0335--31.31--21.00------
Visen Pharmaceuticals-100.00bn-100.00bn3.88bn54.00--3.70----------9.22----------------------------0.0014------26.98------
Qyuns Therapeutics Co Ltd362.43m-216.98m4.61bn337.00--17.79--12.71-0.9769-0.97691.631.150.29034.059.141,069,106.00-17.90---28.45--72.44---61.64--1.43-23.190.7466------33.91------
Jacobio Pharmaceuticals Group Co Ltd227.81m-51.64m4.80bn211.00--4.90--21.06-0.0667-0.06670.29451.240.1547--7.97886,437.60-3.51-36.09-4.01-39.58100.0065.67-22.67-283.16----0.1415--145.13--56.64--29.33--
TYK Medicines Inc121.05k-316.86m4.85bn163.00--11.72--40,063.00-0.8545-0.85450.00031.090.0002----791.18-42.68------13.08---263,981.30------0.3215-------1.18------
Laekna Inc0.00-271.77m5.72bn84.00--6.48-----0.7389-0.73890.001.980.00----0.00-27.79---34.25--------------0.1383------31.05------
Edding Genor Group Holdings Ltd253.42m22.79m6.19bn17.0068.821.31178.1124.410.04490.04490.4882.370.1724--5.2110,559,100.001.46-48.631.72-55.1999.5697.888.45-2,303.07----0.0007----73.7192.40---43.79--
MiRXES Holding Co Ltd-100.00bn-100.00bn7.01bn347.00--7.87----------2.99------------------------3.83--0.1682---16.14---33.37------
Data as of Feb 16 2026. Currency figures normalised to Jacobio Pharmaceuticals Group Co Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

6.45%Per cent of shares held by top holders
HolderShares% Held
Hillhouse Investment Management Ltd. (Hong Kong)as of 23 May 202539.34m4.97%
E Fund Management Co., Ltd.as of 30 Jun 20254.36m0.55%
First Trust Advisors LPas of 06 Feb 20261.59m0.20%
SSgA Funds Management, Inc.as of 05 Feb 20261.51m0.19%
China Asset Management Co., Ltd.as of 28 Nov 2025949.80k0.12%
Allianz Global Investors GmbHas of 31 Oct 2025947.70k0.12%
CSOP Asset Management Ltd.as of 30 Jun 2025900.00k0.11%
JPMorgan Asset Management (China) Co Ltd.as of 30 Jun 2025840.60k0.11%
BlackRock Fund Advisorsas of 05 Feb 2026332.40k0.04%
TIAA-CREF Investment Management LLCas of 31 Dec 2025286.80k0.04%
More ▼
Data from 30 Jun 2025 - 09 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.